文献速递肾移植

肾移植中多瘤病毒再激活与针对肾脏特异性自身抗原的免疫应答

Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation.
PubMed 文献 · J Am Soc Nephrol · 2016-11-07

该研究报道了一项试验的10年结果(n=193)及嵌套病例对照研究(n=40),发现他克莫司较环孢素急性排斥和移植物丢失更少、移植功能更好;BK病毒血症免疫抑制最小化者10年结局与无病毒血症者相似。病例对照中多瘤病毒再激活者第1年抗纤连蛋白/IV型胶原抗体更常见,且这些抗体与更多急性排斥相关。

要点

  • 他克莫司组较环孢素组10年急性排斥11% vs 22%(P=0.05),移植物丢失9% vs 22%(P=0.01)。
  • BK病毒血症免疫抑制最小化者10年结局与无病毒血症者相似。
  • 多瘤病毒再激活者第1年抗FN/Col-IV抗体48% vs 无再激活者11%(P=0.04)。

核心结论

  • 这些数据证明最小化免疫抑制治疗BK病毒血症具有长期安全性和有效性。
  • 这些结果表明多瘤病毒再激活与针对肾脏特异性自身抗原的免疫应答相关,可能通过尚不清楚的机制增加急性排斥风险。

研究设计与样本

  • 报告一项试验的10年结果(n=193)及一项嵌套病例对照研究(n=40)。

主要发现

  • 10年时,他克莫司组较环孢素组急性排斥更少(11% vs 22%,P=0.05),移植物丢失更少(9% vs 22%,P=0.01),移植功能更好(eGFR 65±19 vs 50±24 ml/min per 1.73 m2,P<0.001)。
  • 因BK病毒血症行免疫抑制减量者10年结局与无病毒血症者相似。
  • 病例对照研究中,多瘤病毒再激活者第1年抗FN/Col-IV抗体较无再激活者更常见(48% vs 11%,P=0.04)。
  • 有抗FN/Col-IV抗体者较无这些抗体者急性排斥更多(38% vs 8%,P=0.02)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Humoral immune responses against donor antigens are important determinants of long-term transplant outcomes. Reactivation of the polyomavirus BK has been associated with de novo antibodies against mismatched donor HLA antigens in kidney transplantation. The effect of polyomavirus reactivation (BK viremia or JC viruria) on antibodies to kidney-specific self-antigens is unknown. We previously reported excellent 5-year outcomes after minimization of immunosuppression for BK viremia and after no intervention for JC viruria. Here, we report the 10-year results of this trial (n=193) along with a nested case-control study (n=40) to explore associations between polyomavirus reactivation and immune responses to the self-antigens fibronectin (FN) and collagen type-IV (Col-IV). Consistent with 5-year findings, subjects taking tacrolimus, compared with those taking cyclosporin, had less acute rejection (11% versus 22%, P=0.05) and graft loss (9% versus 22%, P=0.01) along with better transplant function (eGFR 65±19 versus 50±24 ml/min per 1.73 m2, P<0.001) at 10 years. Subjects undergoing immunosuppression reduction for BK viremia had 10-year outcomes similar to those without viremia. In the case-control study, antibodies to FN/Col-IV were more prevalent during year 1 in subjects with polyomavirus reactivation than in those without reactivation (48% versus 11%, P=0.04). Subjects with antibodies to FN/Col-IV had more acute rejection than did those without these antibodies (38% versus 8%, P=0.02). These data demonstrate the long-term safety and effectiveness of minimizing immunosuppression to treat BK viremia. Furthermore, these results indicate that polyomavirus reactivation associates with immune responses to kidney-specific self-antigens that may increase the risk for acute rejection through unclear mechanisms.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Seifert ME, Gunasekaran M, Horwedel TA, et al. Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation. J Am Soc Nephrol. 2016. PMID: 27821629. doi:10.1681/ASN.2016030285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。